Letrozole and Cabergoline Co-administration in the Early Luteal Phase for Prevention of OHSS in a High Risk Patient Undergoing Ovarian Stimulation for IVF
|Fatemi HM1, Kyrou D2*, Papanikolaou EG3, Al Buarki H1 and Garcia Velasco J4|
|1Vrije Universiteit Brussel, Centre for reproductive medicine/RHH Kuwait, Laarbeeklaan 101, 1090 Brussels, Belgium|
|2Unit for Human Reproduction, Department of Obstetrics and Gynaecology, Medical School, Papageorgiou General Hospital, Aristotle University of Thessaloniki, Thessaloniki 54603, Greece|
|3Human Reproduction & Genetics Foundation, Adrianoupoleos 6, 55133 Kalamaria, Thessaloniki, Greece|
|4IVI-Madrid, Rey Juan Carlos University, Madrid, Spain|
|*Corresponding Author :||Kyrou D
Unit for Human Reproduction
Department of Obstetrics and Gynaecology
Medical School, Papageorgiou General Hospital
Aristotle University of Thessaloniki
Nea Efkarpia Peripheral Road
Thessaloniki 54603, Greece
E-mail: [email protected]
|Received May 31, 2012; Accepted October 17, 2012; Published October 17, 2012|
|Citation: Fatemi HM, Kyrou D, Papanikolaou EG, Al Buarki H, Garcia Velasco J (2012) Letrozole and Cabergoline Co-administration in the Early Luteal Phase for Prevention of OHSS in a High Risk Patient Undergoing Ovarian Stimulation for IVF. J Fert In Vitro 2:111. doi: 10.4172/2165-7491.1000111|
|Copyright: © 2012 Fatemi HM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Background: In the face of a high risk for OHSS situation, many strategies have been suggested to prevent it; however, none of the proposed strategies completely prevents OHSS. We report a case of a successful IVF pregnancy and complete prevention of OHSS in a patient at high risk of developing OHSS by co-administration of a dopamine agonist and an aromatase inhibitor during the early luteal phase of the cycle.
Case: A 21-year-old patient with primary infertility, secondary to severe oligoasthenospermia of the male partner was stimulated with rec-FSH/GnRH antagonist protocol. Final oocyte maturation was achieved by administration of 5000 IU of HCG. Due to the high risk of OHSS, patient received directly post oocyte retrieval up to the day of embryo transfer, daily 5 mg Letrozole and 0.5 mg Cabergoline. One embryo was transferred on day 5 post oocyte retrieval.The patient did not develop any early nor late OHSS while a succesful ongoing pregnancy was achieved.
Conclusion: Our findings suggest that the use of cabergoline and letrozole in the early luteal phase for the prevention of OHSS, in patients triggered with hCG, might be a potential new strategy. However their use and effect should be further investigated in prospective randomized studies.